Navigation Links
Ventus Medical Announces PROVENT(R) Sleep Apnea Therapy Recognized by The Wall Street Journal 2009 Technology Innovation Awards
Date:9/21/2009

BELMONT, Calif., Sept. 21 /PRNewswire/ -- Ventus Medical, a privately-held medical device company focused on improving the lives of patients with sleep-disordered breathing, today announced that the company's PROVENT(R) Sleep Apnea Therapy received the Runners-Up Award in The Wall Street Journal 2009 Technology Innovation Awards, Medical Devices category. The results were published in the September 14, 2009 edition of The Wall Street Journal.

(Logo:http://www.newscom.com/cgi-bin/prnh/20090409/SF96872LOGO)

"We are excited to be recognized by The Wall Street Journal for our PROVENT Sleep Apnea Therapy," said John McCutcheon, President and Chief Executive Officer at Ventus Medical. "We are proud of this innovative treatment and the potential benefit it brings to the more than 50 million Americans who have obstructive sleep apnea and those not satisfied with standard therapies. We continue our commitment to developing innovative solutions for people affected by sleep-disordered breathing."

According to The Wall Street Journal, winners were selected from nearly 500 nominations across numerous categories from nearly 20 countries. Of those, more than 180 nominations cleared preliminary screening and were passed on for review by a panel of judges comprised of research institutions, venture capital firms and other companies. Judges evaluated whether innovations were truly groundbreaking and also looked at whether their application would be particularly useful in a time of economic hardship. Only seven percent of entries screened by the judges received an award.

About PROVENT Therapy

PROVENT Therapy is a prescription device indicated for the treatment of obstructive sleep apnea (OSA). It is an easy to use and disposable treatment that works across mild, moderate, and severe OSA. The treatment utilizes nasal expiratory positive airway pressure and has been clinically shown to reduce sleep apnea. It incorporates a novel MicroValve design that is placed over the nostrils and secured with hypoallergenic adhesive. During inhalation, the valve opens allowing nearly unobstructed airflow, and during exhalation, the valve closes, limiting airflow through two small openings, which increases expiratory pressure, helping to keep the airway open.

Currently, PROVENT Therapy is available in limited locations in the United States with the assistance and support of professional sleep physicians. PROVENT Therapy may not be appropriate for everyone. For more information, please visit www.ProventTherapy.com.

Sleep-Disordered Breathing

Sleep-disordered breathing broadly refers to a group of disorders characterized by abnormalities of breathing pattern (such as stopping breathing) or the abnormal reduction in the volume of breaths while sleeping. OSA is the most common type of sleep-disordered breathing. An estimated 50 million people in the United States suffer from OSA, which occurs when the upper airway (near the back of the mouth) collapses during sleep, obstructing the airway and preventing air from entering the lungs. OSA is caused by multiple factors, including sleep-induced relaxation of the throat muscles and tongue, enlarged tonsils and adenoids, an abnormally small airway diameter in the back of the mouth and throat, and extra soft tissue in and around the throat due to being overweight.

About Ventus Medical

Ventus Medical is a medical device company focused on improving the lives of patients with sleep-disordered breathing. Located in Belmont, California, Ventus Medical has developed and markets PROVENT Therapy, an innovative, clinically-proven treatment for OSA. Existing OSA solutions do not always meet patients' needs. Through truly innovative technology, solid clinical evidence, and a focus on the patient, Ventus Medical seeks to deliver consumer-preferred, physician-recommended solutions. The company is privately-held and funded by De Novo Ventures, Mohr Davidow Ventures, and Johnson & Johnson Development Corporation.


'/>"/>
SOURCE Ventus Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rochester Medical Announces New Opportunity in the United Kingdom
2. Webmedx Launches New Data-Mining Solution for Medical Transcription and Speech-Generated Documents
3. Occlutech and IZASA Obtains Favourable Ruling in Proceeding Initiated by AGA Medical in Spain
4. FDA Awards Three Grants Designed to Stimulate Development of Pediatric Medical Devices
5. Adnan H. Tahir, M.D., Named Chief Medical Officer of Sisters of Charity Health System
6. GSK Limits Medical Education Funding to Independent Programs With Highest Impact on Patient Care
7. Alere Executive Keynote at DMAA Conference Stresses Combining Medical and Health Improvement Models to Bring About Cost-Effective Changes in Healthcare Reform
8. PLC Medical Systems to Demonstrate RenalGuard(R) at TCT 2009, Building on Success at ESC 2009
9. Motorolas 802.11n Wireless LAN Solution Improves Patient Care and Wireless Security at Memorial Medical Center of Western Michigan
10. Winner Medical Solely Sponsored the 2009 China Medical Textile Industry Forum
11. ATS Medical Announces Implant Milestone for the ATS 3f Aortic Bioprosthesis Achieved at Columbia University Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... new solution that enables organizations to easily reprint customer invoices, bills, statements and ... automates all of the steps needed to retrieve and print the documents and ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... Monthly Monitoring Healthcare products at competitive pricing. Verisys through its ... Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are delighted to be ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, ...                  , How will the new EU MDR language change the way ...
(Date:3/23/2017)... ... ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: a call to heal ... creation of published author, Desiree M Webb, a registered nurse, minister of music, speaker, ... married to her husband, Paul, for over twenty-nine years. Desiree enjoys writing, beach ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 2017  Ethicon* today announced the completion of ... held medical device company that manufactures and markets ... treatment of Gastroesophageal Reflux Disease (GERD). This acquisition ... portfolio of minimally invasive options for patients suffering ... of the transaction have not been disclosed. ...
(Date:3/23/2017)... A research report by Mordor Intelligence ... reach USD 7.2 billion by the end of 2021 and ... procedure in which a sample is preserved prior to its ... since the methods are often allowing repeated testing. The report ... shared procedures in the lab. In many life science labs, ...
(Date:3/23/2017)... 2017  Drug diversion is a significant contributing ... overdoses. A new oral fluid monitoring test, announced ... reports more detailed and actionable information to clinicians ... therapy adherence, patient safety, and help to identify ... fluid Rx Evaluation (CORE) system is the first ...
Breaking Medicine Technology: